Feedback / Questions
bertilimumab (iCo-008) - iCo Therapeutics, Alexion Pharma
Bertilimumab: Expiry of patents between 2021 and 2022
(Immune Pharma)
-
Oct 25, 2018 -
Corporate Presentation
Patent
•
Immunology • Inflammation • Inflammatory Bowel Disease
https://d1io3yog0oux5.cloudfront.net/_052e2a52d1e37159a67670b1fa252a5c/immunepharma/db/277/1833/pdf/IMNP+Presentation+2018-10.pdf
Oct 25, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious